AI
| Followers | 229 |
| Posts | 14791 |
| Boards Moderated | 1 |
| Alias Born | 03/29/2014 |
Saturday, November 17, 2018 12:50:08 PM
approx. 93 total patients should live to 36 months or 28% (not 27%) of the trial’s enrollment.
Weird, huh? It does seem from our i-hub chart work (you, lykiri, meirluc, me, and several others), that my chicken scratchings of the monthly attrition rates (and subsequent discussions of it) based on that chart were very close to correct.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143791138&txt2find=LTFU
As were Brian Wells' numbers in his blog,
"Recently Released Interim Data On Northwest Biotherapeutics' DCVax-L Hints Of An Upcoming Blockbuster Cancer Treatment In Glioblastoma"
22.4 + 5.7 = 28.1% blended 36 month OS (as predicted)
https://seekingalpha.com/instablog/49123839-bwells18/5234734-recently-released-interim-data-northwest-biotherapeutics-dcvax-l-hints-upcoming-blockbuster
Recent NWBO News
Kona Gold Beverages, Inc. Announces Strategic Initiatives and Corporate Direction Changes • KGKG • Aug 2, 2024 2:00 PM
POET and Luxshare Tech Expand Product Offerings for Artificial Intelligence Networks • POET • Aug 1, 2024 9:28 AM
Management Discusses Financial Filings of Global Arena Holding Inc., for 10-K 2023 and 10-Q, 1st Quarter 2024 • GAHC • Aug 1, 2024 9:14 AM
VAYK Announces LOI to Acquire $1 Million Home Service Company to Support Airbnb Business • VAYK • Aug 1, 2024 9:00 AM
Duane Forrester Joins INDEXR as SVP of Search • MONI • Jul 31, 2024 11:46 AM
Lingerie Fighting Championships Help Fulfill Death-Bed Promise With First Major Motion Picture • BOTY • Jul 31, 2024 9:00 AM
